Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

SI-BONE Gelecekteki Büyüme

Future kriter kontrolleri 1/6

SI-BONE kazanç ve gelirin sırasıyla yıllık 21.4% ve 16.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 22.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -17.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

21.4%

Kazanç büyüme oranı

22.9%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.6%
Gelir büyüme oranı	16.5%
Gelecekteki özkaynak getirisi	-17.2%
Analist kapsamı	Good
Son güncelleme	22 Aug 2024

Gelecekteki son büyüme güncellemeleri

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

Feb 29

Recent updates

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Sep 25

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

Apr 01

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

Feb 29

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:SIBN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	228	-23	N/A	N/A	7
12/31/2025	195	-32	N/A	N/A	9
12/31/2024	166	-37	N/A	N/A	9
6/30/2024	151	-41	-26	-18	N/A
3/31/2024	144	-43	-23	-16	N/A
12/31/2023	139	-43	-27	-19	N/A
9/30/2023	132	-44	-32	-23	N/A
6/30/2023	124	-48	-38	-28	N/A
3/31/2023	117	-55	-49	-39	N/A
12/31/2022	106	-61	-51	-42	N/A
9/30/2022	100	-65	-57	-48	N/A
6/30/2022	96	-66	-57	-50	N/A
3/31/2022	92	-62	-50	-44	N/A
12/31/2021	90	-57	-46	-40	N/A
9/30/2021	87	-51	-40	-35	N/A
6/30/2021	85	-45	-36	-31	N/A
3/31/2021	77	-43	-34	-31	N/A
12/31/2020	73	-44	-33	-31	N/A
9/30/2020	71	-44	-34	-32	N/A
6/30/2020	67	-46	-36	-33	N/A
3/31/2020	69	-42	-37	-34	N/A
12/31/2019	67	-38	-34	-32	N/A
9/30/2019	63	-35	-31	-29	N/A
6/30/2019	60	-28	-25	-24	N/A
3/31/2019	58	-23	-18	-17	N/A
12/31/2018	55	-17	-15	-15	N/A
9/30/2018	54	-17	-13	-12	N/A
6/30/2018	52	-18	-15	-14	N/A
3/31/2018	49	-21	N/A	-17	N/A
12/31/2017	48	-23	N/A	-18	N/A
3/31/2017	44	-21	N/A	-16	N/A
12/31/2016	42	-21	N/A	-17	N/A
3/31/2016	40	-27	N/A	-25	N/A
12/31/2015	41	-28	N/A	-27	N/A
9/30/2015	42	-32	N/A	-27	N/A
3/31/2015	40	-32	N/A	-29	N/A
12/31/2014	40	-28	N/A	-26	N/A
12/31/2013	49	-6	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SIBN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: SIBN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: SIBN önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: SIBN şirketinin gelirinin (yıllık 16.5% ) US pazarından (yıllık 8.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SIBN şirketinin gelirinin (yıllık 16.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SIBN 3 yıl içinde kârsız olması bekleniyor.

SI-BONE Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

SI-BONE, Inc. Revises Financial Guidance for 2024

Si-Bone, Inc. Increases Revenue Guidance for 2024

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Recent updates

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Revises Financial Guidance for 2024

SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Si-Bone, Inc. Increases Revenue Guidance for 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

New minor risk - Profitability

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2026

CEO & Director recently sold US$809k worth of stock

SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Forecast to breakeven in 2026

SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Lead Independent Director notifies of intention to sell stock

Executive Chairman recently sold US$141k worth of stock

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Price target decreased by 7.3% to US$28.38

SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Executive Chairman exercised options and sold US$337k worth of stock

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods

Executive Chairman notifies of intention to sell stock

CEO & Director recently sold US$189k worth of stock

Executive Chairman notifies of intention to sell stock

Independent Director recently sold US$616k worth of stock

SI-BONE, Inc. Revises Revenue Guidance for the Year 2023

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO & Director recently sold US$224k worth of stock

President of Commercial Operations notifies of intention to sell stock

Executive Chairman exercised options and sold US$5.1m worth of stock

SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Key Executive notifies of intention to sell stock

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 16% to US$24.50

President of Commercial Operations notifies of intention to sell stock

CEO & Director recently sold US$226k worth of stock

Executive Chairman notifies of intention to sell stock

SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023

SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System

Price target decreased to US$22.38

Executive Chairman recently sold US$105k worth of stock

CEO & Director notifies of intention to sell stock

Third quarter 2022 earnings: EPS exceeds analyst expectations

SI-BONE, Inc. Updates Revenue Guidance for the Year 2022

SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Executive Chairman recently sold US$138k worth of stock

SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite